Record CStone Funding Heralds New Era For China Startups

With $150m in hand and a pipeline covering five therapeutic areas, CStone has already broken the record for the largest Series A investment in a Chinese biopharma startup. If that's not impressive enough, add a CEO from big pharma and support from China’s largest CRO.

More from China

More from Focus On Asia